Primary |
Drug Use For Unknown Indication |
49.1% |
General Anaesthesia |
18.9% |
Lung Disorder |
7.5% |
Prophylaxis |
7.5% |
Sedation |
7.5% |
Agitation |
3.8% |
Depression |
1.9% |
Labour Pain |
1.9% |
Tachypnoea |
1.9% |
|
Acute Generalised Exanthematous Pustulosis |
11.1% |
Cardiac Arrest |
11.1% |
Drug Exposure During Pregnancy |
11.1% |
Multiple Congenital Abnormalities |
11.1% |
Persistent Left Superior Vena Cava |
11.1% |
Pregnancy |
11.1% |
Respiratory Depression |
11.1% |
Snoring |
11.1% |
Vater Syndrome |
11.1% |
|
Secondary |
Anaesthesia |
22.4% |
General Anaesthesia |
17.5% |
Induction Of Anaesthesia |
13.1% |
Maternal Exposure Timing Unspecified |
7.0% |
Product Used For Unknown Indication |
5.9% |
Drug Use For Unknown Indication |
5.6% |
Epidural Anaesthesia |
3.4% |
Pain |
3.2% |
Surgery |
2.9% |
Infection |
2.4% |
Antibiotic Prophylaxis |
2.2% |
Abdominal Pain |
1.9% |
Sedation |
1.9% |
Local Anaesthesia |
1.7% |
Postoperative Care |
1.7% |
Therapeutic Procedure |
1.7% |
Premedication |
1.5% |
Prophylaxis |
1.5% |
Vulvovaginitis Streptococcal |
1.4% |
Hysterectomy |
1.2% |
|
Anaphylactic Shock |
18.3% |
Shock |
14.4% |
Urticaria |
12.5% |
Tachycardia |
6.7% |
Rash |
4.8% |
Circulatory Collapse |
3.8% |
Hypotension |
3.8% |
Pancreatitis Acute |
3.8% |
Transaminases Increased |
3.8% |
Weight Decreased |
3.8% |
Cholestasis |
2.9% |
Oxygen Saturation Decreased |
2.9% |
Paresis |
2.9% |
Respiratory Gas Exchange Disorder |
2.9% |
Therapeutic Response Prolonged |
2.9% |
Anaemia |
1.9% |
Disseminated Intravascular Coagulation |
1.9% |
Erythema Multiforme |
1.9% |
Generalised Erythema |
1.9% |
Guillain-barre Syndrome |
1.9% |
|
Concomitant |
Induction Of Anaesthesia |
15.4% |
Anaesthesia |
14.7% |
Product Used For Unknown Indication |
11.5% |
Drug Use For Unknown Indication |
10.0% |
Prophylaxis |
6.8% |
Unevaluable Event |
5.9% |
Sedation |
4.6% |
Thrombosis Prophylaxis |
4.2% |
Liver Transplant |
3.1% |
Renal Transplant |
2.8% |
Respiratory Tract Infection |
2.7% |
Analgesia |
2.4% |
General Anaesthesia |
2.2% |
Pain |
2.2% |
Septic Shock |
2.2% |
Neuromuscular Blockade Reversal |
2.0% |
Epidural Anaesthesia |
1.9% |
Hypertension |
1.9% |
Supplementation Therapy |
1.9% |
Haemorrhagic Disorder |
1.6% |
|
Anaesthetic Complication |
9.1% |
Pharmaceutical Product Complaint |
9.1% |
Renal Failure Acute |
6.8% |
Septic Shock |
6.8% |
Tachycardia |
6.8% |
Thrombocytopenia |
6.8% |
Venous Thrombosis Limb |
5.7% |
Hypotension |
4.5% |
Respiratory Failure |
4.5% |
Toxic Epidermal Necrolysis |
4.5% |
Urticaria |
4.5% |
Coagulopathy |
3.4% |
Overdose |
3.4% |
Pancreatitis |
3.4% |
Pancreatitis Acute |
3.4% |
Rhabdomyolysis |
3.4% |
Skin Test Positive |
3.4% |
Toxic Skin Eruption |
3.4% |
Uterine Atony |
3.4% |
Ventricular Fibrillation |
3.4% |
|
Interacting |
Depressive Symptom |
25.0% |
Nausea |
25.0% |
Parathyroid Gland Operation |
25.0% |
Surgery |
25.0% |
|
Serotonin Syndrome |
100.0% |
|